The agreement also gives Pfizer exclusive rights to the use of this vaccine targeting the tumor specific EGFR mutant EGFRvIII in other potential indications.
On April 16, 2008, Pfizer and Celldex announced that they entered into an agreement under which Pfizer would be granted an exclusive worldwide license to CDX-110, currently being evaluated in a Phase II study for the treatment of glioblastoma multiforme.